It’s estimated that 90% of retail investors lose money. We help you beat those odds with concise research, education and more. Click here to see our offerings.
- Kadmon is a clinical-stage biopharmaceutical company focused on immune and fibrotic diseases as well as immuno-oncology therapies
- Kadmon’s lead asset (Awaiting PDUFA decision) is Belumosudil (KD025) which is in development for Systemic Sclerosis (SSc) and Chronic GVHD (cGVHD)
- To see Kadmon’s Phase 1&2 assets, click here